HELP

$13.12-$0.49 (-3.60%)prev close

Compare

Change+$5.39

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$958.7M

73M shares

52-week range

$3.76 – $14.35

88% from low

Exchange

NASDAQ

P/E LTM (FWD)

— (29.4)

Run the fair-value model →

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$32M	—	$-2.69	$-2.99–$-2.54	—	4
2028	$10M	-69.8%	$-2.20	$-4.92–$-0.51	—	2
2029	$195M	+1936.5%	$-1.10	$-3.39–$0.78	—	6
2030	$509M	+161.2%	$0.45	$0.10–$1.00	29.4×	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-14	$-0.84	$-0.91	-8.8%
2026-06-30	$-1.04	$-0.96	+8.1%
2026-02-13	$-0.53	$-0.99	-87.3%
2025-11-13	$-0.74	$-1.39	-87.8%
2025-08-13	$-0.96	$-1.10	-14.7%
2025-07-01	$-0.85	$-1.01	-18.7%
2025-02-11	$-0.73	$-0.37	+49.5%
2024-11-13	$-0.98

DCF fair valuemodel estimate

Intrinsic value

$3.53

Price

$13.12

Implied downside

-73%

Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

www.helus.com

Employees: 50
IPO / List date: Nov 10, 2020

Held by traders on TradeandTell

No one on the platform currently holds HELP.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in HELP as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded HELP yet.

$HELP chatter on StockTwits

And Its Gone@BioBum6h
$PSIL own the ETF!! Own them ALL $DFTX $CMPS $HELP $ATAI
View on StockTwits ↗
Millionaire11@Millionaire11Bullish8h
@Amb8675309 $DFTX will do fine in the long run. Although, the reality is it’s valued very high compared to competitors. Either $DFTX needs to come down or $CMPS and $HELP needs to go up. All will do great long term.
View on StockTwits ↗
GreatStockPix.com@GSP14h
My Day Trading Watch List Video for September 16th in About 2 Minutes: $IPW $RUM $VEEA $VRA $HELP .
View on StockTwits ↗
Sailingsoon@SailingsoonBullish16h
$HELP https://event.webcasts.com/starthere.jsp?ei=1775809&tp_key=a369166978&tp_special=8
View on StockTwits ↗
Da Bear@finckBullish17h
$HELP this is about to moon
View on StockTwits ↗
Daniel Oliveira@Equibles18h
$HELP Equibles has it in the filing data. Cybin Inc. Chief Growth Officer Glavine Paul reported buying 100,000 HELP shares on September 8, 2026, worth about $1.25 million, in a non-derivative Form 4.
View on StockTwits ↗
Thomas Prindle@brunoq1418h
$DFTX At present no competition in GAD. $HELP has HLP004 in development, and $LLY may switch one of the drugs they acquired to GAD, but you're looking at several years for both of those.
View on StockTwits ↗
Dustin M George@brodobagginz19h
$CMPS rough day for the sector - scaling back in here along with small bois in $DFTX $GHRS and $HELP - glta :)
View on StockTwits ↗
Burkey@SibtsenBullish20h
$CMPS & $HELP I place now this card at opening!
View on StockTwits ↗
GreatStockPix.com@GSP23h
$SPY $TRUG $HELP $SBET $S
View on StockTwits ↗
Jasper@RuddyRollsBullish1d
$HELP golden ticket
View on StockTwits ↗
Jasper@RuddyRollsBullish1d
$HELP Still the best deal in the space in terms of mkt cap, yearly performance and immediately pending upside: HELP $960m mkt cap +123 per cent GHRS$1.91b +130 per cent CMPS $2b +179 per cent DFTX $5.4b +324 per cent Analyst consensus is for $42 a share with some noteable recent calls at $60-$70. The multiple and repeated late-stage major insider buys are suggesting we have a real winner on deck. Break of the annual high of$14.35 now to send us to $18-$22 pre data drop. Then a move to $30-$60 on clean-win to blow out data. This is our time to shine. Don't miss out - load up like Eric and Paul before the train leaves the station. Carpe Diem
View on StockTwits ↗
JusaVaan@JusaVaan1d
@StockArbitrage I think it’s just that a) investors knew already, it’s going to be good - although of course some derisking always happens b) market cap has been already reasonably high, i.e. expectations baked on, c) now it’s going to be quieter for a whilw with catalysts, so investors might be moving where catalysts are imminent ($CMPS, also $HELP)
View on StockTwits ↗
Millionaire11@Millionaire11Bullish1d
$CMPS $DFTX $HELP $ATAI $CMPS has the largest Phase 3 trials for single indication, randomized/double-blind designs, placebo/active-control comparisons, large N, standardized synthetic psilocybin, 26–52 week follow-up. $CMPS has the most in depth studies in the whole industry. If COMP360 doesn’t get approved due to lack of rigour none of them will. (Bullish on the whole industry btw)
View on StockTwits ↗
Mijo@MurseOMoney1d
Don’t forget about $HELP & $TRUFF 🫡
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.